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Boston, MassachusettsNearly one-half of patients with heart failure have preserved
ejection fraction (HFpEF), and the prevalence appears to be
rising (1). Patients with HFpEF experience similar patterns
of morbidity and functional decline as do those with heart
failure and reduced ejection fraction (HFrEF) (2,3), but few
effective treatments are available. Attempts to deploy ther-
apies of proven efﬁcacy in HFrEF, including angiotensin-
converting enzyme inhibitors and angiotensin receptor
blockers, to the beneﬁt of patients with HFpEF have so farSee page 263been unsuccessful (4–6). Distinct patterns of structural
remodeling and this differential response to therapy suggest
that HFpEF and HFrEF are 2 discrete entities with fun-
damentally different pathophysiologies (7). Progress in
treating HFpEF will require new constructs for under-
standing HF pathogenesis that illuminate alternative mech-
anisms and therapeutic targets.
The last decade has seen considerable progress in identi-
fying some of the diverse pathophysiological mechanisms that
contribute to HFpEF. Abnormalities of passive left ventric-
ular (LV) stiffness and active myocardial relaxation that im-
pair LV ﬁlling in diastole at rest or during exercise appear to
be central (8–10). However, several other factors, including
enhanced central aortic stiffness and impaired ventricular-
vascular coupling (11), chronotropic incompetence (12,13),
limited vasodilator reserve (13), and pulmonary hypertension
(14,15), may also play important roles. A common thread
uniting these mechanisms may be endothelial dysfunction as
a consequence of accumulated comorbidities that are com-
mon in patients with HFpEF such as hypertension, diabetes,
obesity, chronic kidney disease, and anemia. Endothelial
abnormalities in the peripheral, coronary, and pulmonary
vascular circulation, respectively, might provide a unifying
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vascular resistance that are characteristic of the HFpEF
syndrome (16). Experimental and clinical data suggest that
both peripheral and central endothelial dysfunction
contribute to HF pathogenesis in those with reduced EF
(16,17). A recent observational study suggests that the same
may be true for patients with HFpEF (18).
In the current issue of the Journal, Paulus and Tschope
(19) propose a new theoretical framework for understanding
HFpEF that postulates a central role for endothelial
dysfunction in HF development. Through a comprehensive
synthesis of experimental data regarding abnormalities
in myocyte structure, function, and signaling in HFpEF,
including their own recent work in endomyocardial biopsy
specimens from HFpEF patients, they make the case that
many of the cardiovascular abnormalities in HFpEF can be
understood as the downstream consequence of inﬂammation
associated with comorbid medical illness. They postulate that
obesity, hypertension, diabetes, chronic obstructive pulmo-
nary disease, anemia, and chronic kidney disease conspire to
create a systemic inﬂammatory state that promotes coronary
microvascular endothelial dysfunction. Endothelial inﬂam-
mation results in generation of reactive oxygen species and
reduces NO bioavailability, which in turn results in lower
levels of cyclic guanosine monophosphate (GMP) and lower
activity of protein kinase G (PKG). Declining PKG activity
accelerates pro-hypertrophic signaling and increases myocyte
stiffness by promoting hypophosphorylation of titin, en-
hancing diastolic dysfunction and ventricular stiffening.
The disruptive concept at the heart of this new paradigm
is the shift away from the traditional emphasis on afterload
excess toward inﬂammation as the primary stimulus for
hypertrophy and diastolic dysfunction. Although the inves-
tigators do not discount an important role for hypertension
in the pathophysiology of HFpEF, they view hypertension
as merely one of many comorbidities fueling systemic
inﬂammation, oxidative stress, and endothelial dysfunction
in this syndrome. HFpEF in this model reﬂects the cumu-
lative expression of structural and functional changes related
to a range of comorbidities, not any one in particular; even
though hypertension may be commonly present, it is neither
necessary nor sufﬁcient for HFpEF development. One
appeal of this formulation is that it provides a possible
rationale for the substantial clinical heterogeneity of
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bidity proﬁle between men and women (20) and the
development of HFpEF at a younger age in male, obese, and
diabetic patients (21). Moreover, this framework provides
a potential mechanism for the transition from “compen-
sated” hypertensive heart disease to HFpEF, which occurs in
some patients but not others. Whereas aging and hyper-
tension alone may provide sufﬁcient substrate for the
development of HFpEF in some patients, accumulated
comorbidities may accelerate the process in others.
The notion that comorbid medical illness might play an
important role in HF pathogenesis is not new. Independent
of EF, comorbidities are common in HF patients and are
a recognized contributor to adverse outcomes including
hospitalization and mortality (22). In the I-PRESERVE
(Irbesartan in Heart Failure With Preserved Ejection Frac-
tion) trial, nearly 40% of deaths in HFpEF patients were
attributed to noncardiovascular causes (23), and diabetes,
chronic obstructive pulmonary disease, and renal dysfunction
(estimated glomerular ﬁltration rate) were identiﬁed as
independent predictors of mortality after multivariable
adjustment (24). Obesity, anemia, diabetes, and chronic
kidney disease have each been associated with unique
structural and functional changes in the heart and vascula-
ture in HFpEF patients (21), lending credence to the notion
that much of the pathology of HFpEF may simply reﬂect
the synergistic expression of these comorbid illnesses.
Are comorbidities alone a sufﬁcient explanation for the
pathology of HFpEF? Similar comorbidities are also com-
mon in patients with HFrEF, but they are not thought to
contribute directly to the fundamental pathophysiology of
the disease. In a community-based study, Mohammed et al.
(21) found that even after accounting for comorbidities,
patients with HFpEF displayed cardiovascular structural
and functional abnormalities (concentric LV hypertrophy,
left atrial enlargement, systolic dysfunction, and ventricular-
vascular stiffening) that exceeded those present in age- and
sex-matched healthy and hypertensive control subjects. These
data suggest that HFpEF is likely more complex than a sim-
ple amalgamation of comorbidities; although comorbidities
do inﬂuence ventricular-vascular properties and prognosis,
the development of HFpEF may be fueled by alternative,
disease-speciﬁc mechanisms that are yet to be deﬁned.
Is inﬂammation the thread that unites aging, hyper-
tension, and comorbidities to precipitate HFpEF? Inﬂam-
mation is detectable in many patients with HF, including
those with reduced EF, and is associated with worse prog-
nosis (25–28). However, anti-inﬂammatory treatments in-
cluding antitumor necrosis factor-alpha therapies (29,30)
and 3-hydroxy-3-methylglutaryl coenzyme A reductase
inhibitors (statins) (31,32) have in general failed to improve
clinical outcomes. Although a small retrospective, non-
randomized study suggested potential beneﬁts to statin
treatment in HFpEF, no beneﬁt was seen in the subgroup of
patients with preserved EF enrolled in the large, prospective
GISSI-HF (Gruppo Italiano per lo Studio dellaSopravvivenza nell’Infarto MiocardicodHeart Failure) trial
(32), which randomized patients to rosuvastatin or placebo.
Angiotensin receptor blockers also reduce markers of
inﬂammation (33) and improve endothelial function, but
they have been ineffective in improving outcomes in HFpEF
patients in randomized trials (4,6). Accordingly, it remains
unclear if inﬂammation is an active participant in the
pathogenesis of HF or merely a consequence of accumulated
comorbidities and the advancing disease (34).
While a number of questions remain, the novel para-
digm proposed by these investigators provides a welcome
fresh perspective on the vexing problem of HFpEF. The
hypotheses that are advanced are easily tested and invite
systematic study of anti-inﬂammatory agents, antioxidants,
and agents that enhance NO bioavailability or enhance
activity of the cyclic GMP/PKG pathway in HFpEF.
Preliminary data suggest that sildenaﬁl, which raises
myocardial PKG activity by inhibiting breakdown of cyclic
GMP by phosphodiesterase 5, may improve pulmonary
artery pressures, right ventricular function, and LV relaxa-
tion and distensibility in HFpEF (15) although there was no
impact on functional capacity in the RELAX (Phosphodi-
esterase-5 Inhibition to Improve Clinical Status and Exer-
cise Capacity in Diastolic Heart Failure) trial (35). In the
PARAMOUNT (Prospective comparison of Angiotensin
Receptor Neprilysin Inhibitor with Angiotensin Receptor
Blocker on Examination of Heart Failure with Preserved
Ejection Fraction) study (36), treatment with LCZ696,
a combined angiotensin receptor neprilysin inhibitor that
inhibits natriuretic peptide breakdown and enhances cyclic
GMP activation, was associated with incremental reductions
in circulating N-terminal pro–B-type natriuretic peptide
levels in HFpEF over treatment with valsartan alone.
Phase 3 studies of LCZ696 in HFpEF are under develop-
ment. As clinicians await trials of novel pharmacologic
approaches, however, the growing burden of HFpEF
demands immediate attention. Lack of evidence is no excuse
for inaction, and Paulus and Tschope provide a compelling
rationale for aggressive management of hypertension and
other comorbidities to delay the onset or forestall progres-
sion of HFpEF until better answers are available. Patients
will likely beneﬁt from this comprehensive approach to HF
management even if the speciﬁcs of the theoretical model are
not yet validated.Reprint requests and correspondence: Dr. Akshay Desai,
Cardiovascular Division, Brigham and Women’s Hospital, 75
Francis Street, Boston, Massachusetts 02115. E-mail: adesai@
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